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The membrane protease, corin, has been shown to be the proatrial natriuretic peptide (ANP)-converting enzyme. Like
mice lacking ANP, corin-deficient animals are hypertensive and have cardiac hypertrophy.Vasoactive peptides, such as angioten- o
sin II, endothelin, and vasopressin, are p
tpressor hormones that increase blood
pressure and cardiac remodeling. Thus, h
aone may think that increased levels of a
similar vasoactive substance would be s
ideleterious, causing cardiovascular dam-
age when produced in an unchecked u
tmanner. In fact, some of our best antihy-
pertensive drugs, specifically ACE inhib- z
aitors, are designed to block the prote-
ases that produce these hormones. l
oHowever, increased levels of one family88f vasoactive hormones, the natriuretic e
ceptides, may be desirable because
hey reduce blood pressure and cardiac h
sypertrophy. Hence, it seems reason-
ble to look in patients with hyperten- i
ion and/or congestive heart failure for
nactivating mutations within these natri- f
tretic peptide-converting enzymes; al-
ernatively, drugs that activate these en- (
(ymes might be potential therapeutic
gents for the treatment of cardiovascu- i
iar diseases. Unfortunately, the identity
f these natriuretic peptide-converting snzymes has not been forthcoming. Re-
ent work published in PNAS, however,
as brought the search for the long-
ought proANP convertase to a satisfy-
ng end (Chan et al., 2005).
In mammals, the natriuretic peptide
amily consists of atrial natriuretic pep-
ide (ANP), brain natriuretic peptide
BNP), and C type natriuretic peptide
CNP) (Levin et al., 1998). ANP is stored
n granules in the atria and is released
nto the peripheral circulation upon atrial
tretch resulting from elevated bloodCELL METABOLISM : FEBRUARY 2005
P R E V I E Wtro. This, however, is similar to demon- mice developed normally but had ele-
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Figure 1. A schematic model of corin processing of proANP to ANP 1
Human ANP is synthesized as a preprohormone. Removal of the amino-terminal 26 amino acid signal se-
Pquence produces proANP. The membrane-associated serine protease, corin, cleaves proANP at arginine 124
to produce the mature 28 amino acid disulfide-linked receptor binding form of the peptide. 2pressure. Physiologically, ANP decreases s
blood pressure and cardiac hypertrophy. a
BNP is synthesized in the cardiac ventri- b
cles, but unlike ANP, it is not stored in t
granules. The major effect of BNP is to s
inhibit pressure-induced ventricular fi- c
brosis (Tamura et al., 2000). All known z
actions of ANP and BNP are mediated t
by a transmembrane guanylyl cyclase t
known as natriuretic peptide receptor A (
(Potter and Hunter, 2001). In the clinic, t
serum BNP levels are routinely used to c
predict cardiovascular stress conditions
like congestive heart failure. Additionally, f
intravenous injection of a recombinant r
form of BNP called nesiritide is an FDA s
approved treatment for heart failure. (
CNP, on the other hand, is found in high W
concentrations in cartilage, brain, and
g
endothelial tissue. It appears to primarily
t
stimulate long bone growth because
(loss-of-function mutations in CNP (Chu-
dsho et al., 2001) or its cognate guanylyl
wcyclase receptor, natriuretic peptide re-
cceptor B (Tamura et al., 2004), result in
hdwarfism.
gNatriuretic peptides, like most peptide
bsignaling molecules, are synthesized as
epreprohormones (Figure 1). Removal of
tthe amino-terminal signal sequence
(yields a prohormone. In the case of ANP,
1it is the prohormone that is stored in at-
rrial granules, but production of the ma-
bture receptor binding molecule requires
a second cleavage by a unique mem-
fbrane-associated protease. Several en-
wzymes including thrombin (Corthorn et
aal., 1991) and kallikreins (Moreau et al.,
e1995) can convert proANP to ANP in vi-CELL METABOLISM : FEBRUARY 2005trating that a kinase can phosphorylate v
aprotein in vitro, in that it is suggestive
rut does not prove that the kinase effec-
aive in vitro actually phosphorylates the
Aubstrate in vivo. Thus, the physiologi-
lally relevant proANP converting en-
dyme has eluded identification for over
pwenty years. With the recent publica-
iion of the work of Wu and colleagues
1Chan et al., 2005), however, it appears
phat the proANP convertase has been
fonclusively identified.
pThe cDNA encoding mouse corin was
airst reported as low-density lipoprotein
teceptor related protein-4 because of its
iimilarity to other members of this family
dTomita et al., 1998). Shortly thereafter,
au and colleagues described the analo-
pous human cDNA as a novel cardiac
wype II transmembrane serine protease
bYan et al., 1999) and designated it corin
tue to its high cardiac expression. They
ent on to show that recombinant corin
tould process proANP to ANP in a
iighly sequence-specific manner, sug-
sesting for the first time that corin may
be the proANP converting enzyme (Yan
tt al., 2000). However, since other pro-
feases also convert proANP to ANP
f
Corthorn et al., 1991; Moreau et al.,
995), the identity of the physiologically
Lelevant proANP convertase could not
De definitively established.
To determine whether corin is required
Uor the processing of proANP to ANP in
Mhole animals, Chan and colleagues in-
ctivated the corin gene in mice (Chan
t al., 2005). They found that the corin−/−
Sated levels of proANP and undetect-
ble levels of ANP. Infusion of soluble
ecombinant corin into the knockout
nimals transiently increased mature
NP levels. Consistent with a physio-
ogic proANP converting function, corin-
eficient animals had increased blood
ressure and cardiac hypertrophy, sim-
lar to mice devoid of ANP (John et al.,
995). Interestingly, although corin is ex-
ressed in chondrocytes and was there-
ore a reasonable candidate for the
roCNP convertase, the corin knockout
nimals did not have any obvious skele-
al abnormalities, suggesting that corin
s not essential for mature CNP pro-
uction in vivo. On the other hand, the
bility of the corin−/− mice to convert
roBNP to BNP was not discussed,
hich is unfortunate since corin has
een shown to efficiently accomplish
his task in vitro (Yan et al., 2000).
In conclusion, the positive determina-
ion of corin as the proANP convertase
s a major step forward in our under-
tanding of the hormonal control of
lood pressure. Whether mutations in
he human corin gene will explain some
orms of essential hypertension awaits
urther analysis.
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